C-Path Launches Rare Disease Clinical Outcome Assessment Consortium

The Rare Disease COA Consortium aims to advance patient-focused assessment of clinical benefit in treatment trials for rare diseases
TUCSON, the launch of the a public-private partnership focused on optimizing COA selection during medical product development for rare diseases. The Rare Disease COA Consortium is a collaborative effort among C-Path, the U.S. Food and Drug Administration (FDA), government agencies, as well as key treatments for rare diseases.

Read the source article at AZBio
2022-01-13 16:39:29